Augmenting Venetoclax Activity Through Signal Transduction in AML

Area of Science:

• Hematology
• Oncology
• Molecular Biology

Background:

• Venetoclax (BCL-2 inhibitor) revolutionized acute myeloid leukemia (AML) treatment by targeting leukemic stem cells (LSCs).
• Treatment failure and disease relapse remain significant challenges in venetoclax therapy for AML.
• Resistance mechanisms are heterogeneous, involving genetic/epigenetic changes and upregulation of anti-apoptotic proteins.

Purpose of the Study:

• To review mechanisms of venetoclax resistance in AML, focusing on signal transduction pathways.
• To elucidate how aberrant cell signaling contributes to apoptosis evasion and treatment failure.
• To highlight novel combination strategies targeting signaling pathways to enhance venetoclax efficacy.

Main Methods:

• Review of existing literature on venetoclax resistance mechanisms in AML.
• Analysis of signal transduction pathways implicated in resistance.
• Identification of potential therapeutic targets and combination strategies.

Main Results:

• Aberrant cell signaling pathways (e.g., FLT3, PI3K/AKT/mTOR, RAS) are key drivers of venetoclax resistance.
• These pathways lead to the upregulation of anti-apoptotic mediators, promoting cell survival.
• Constitutively active signaling contributes to refractory disease and relapse.

Conclusions:

• Signal transduction pathways play a critical role in venetoclax resistance in AML.
• Targeting these aberrant pathways, potentially through combination therapies, is crucial for overcoming resistance.
• Developing strategies to disable dysregulated signaling may improve treatment outcomes and prevent relapse in AML patients.